ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Ductal Breast Carcinoma In Situ
Estrogen Receptor Negative
HER2/Neu Negative
Invasive Cribriform Breast Carcinoma
Papillary Breast Carcinoma
Progesterone Receptor Positive
Estrogen Receptor Positive
Stage II Breast Cancer
Stage IIIA Breast Cancer
Invasive Ductal Carcinoma, Not Otherwise Specified

Interventions: Procedure: Therapeutic Conventional Surgery
Radiation: Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment

First Posted Date: 2012-12-21

Last Posted Date: 2017-07-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01754519

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Early Phase 1

Completed

Conditions: Ductal Breast Carcinoma
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Ductal Breast Carcinoma In Situ
Estrogen Receptor Negative
Estrogen Receptor Positive
Invasive Breast Carcinoma
Lobular Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Broccoli Sprout Extract
Other: Pharmacological Study
Other: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2019-10-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT01753908

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Phase 1

Terminated

Conditions: Stage IV Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Recurrent Melanoma

Interventions: Biological: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-12-06

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01744171

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Phase 1

Withdrawn

Conditions: Mucositis
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx

Interventions: Drug: entolimod
Radiation: intensity-modulated radiation therapy
Drug: cisplatin
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-11-19

Last Posted Date: 2013-12-11

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01728480

Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer

Not Applicable

Withdrawn

Conditions: Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage II Verrucous Carcinoma of the Oral Cavity
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage I Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Stage I Squamous Cell Carcinoma of the Oropharynx
Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage II Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: photodynamic therapy
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Drug: temoporfin

First Posted Date: 2012-10-31

Last Posted Date: 2014-09-03

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01718223

Biomarkers in Post-Menopausal Women Receiving Flaxseed

Not Applicable

Completed

Conditions: No Evidence of Disease

Interventions: Other: Clinical Observation
Dietary Supplement: Flaxseed
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2012-10-02

Last Posted Date: 2022-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 258

Registration Number: NCT01698294

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 1

Active, not recruiting

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2012-09-13

Last Posted Date: 2025-06-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 51

Registration Number: NCT01684397

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Karamanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 2 locations

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Phase 2

Terminated

Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx
Chemotherapeutic Agent Toxicity
Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Mucositis
Radiation Toxicity
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Interventions: Dietary Supplement: selenomethionine
Other: placebo
Drug: cisplatin
Radiation: radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2012-09-10

Last Posted Date: 2014-08-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01682031

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇳🇿
Waikato Hospital, Hamilton, New Zealand

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Phase 2

Completed

Conditions: Noncontiguous Stage II Small Lymphocytic Lymphoma
Stage I Grade 2 Follicular Lymphoma
Stage I Grade 3 Follicular Lymphoma
Stage IV Marginal Zone Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Noncontiguous Stage II Grade 2 Follicular Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Stage I Marginal Zone Lymphoma

Interventions: Biological: pegfilgrastim
Biological: rituximab
Other: flow cytometry
Procedure: biopsy
Other: immunohistochemistry staining method
Genetic: western blotting

First Posted Date: 2012-09-10

Last Posted Date: 2017-10-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT01682044

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy

Phase 2

Withdrawn

Conditions: Mucositis
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx

Interventions: Procedure: quality-of-life assessment
Other: placebo
Other: questionnaire administration
Drug: Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules

First Posted Date: 2012-08-28

Last Posted Date: 2013-05-15

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01674374

AI-Powered Research

Premium Access

ROSWELL PARK CANCER INSTITUTE

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer

Biomarkers in Post-Menopausal Women Receiving Flaxseed

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy